Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 1/2022

01-01-2022 | Crohn's Disease | Review

Update: Innate Lymphoid Cells in Inflammatory Bowel Disease

Authors: Weiwei Luo, Li Tian, Bei Tan, Zhaohua Shen, Mengwei Xiao, Shuai Wu, Xiangrui Meng, Xing Wu, Xiaoyan Wang

Published in: Digestive Diseases and Sciences | Issue 1/2022

Login to get access

Abstract

Inflammatory bowel disease (IBD) is a chronic and nonspecific intestinal inflammatory condition with high relapse rate. Its pathogenesis has been linked to dysbacteriosis, genetic and environmental factors. In recent years, a new type of lymphocytes, termed innate lymphoid cells, has been described and classified into three subtypes of innate lymphoid cells—group 1, group 2 and group 3. An imbalance among these subsets’ interaction with gut microbiome, and other immune cells affects intestinal mucosal homeostasis. Understanding the role of innate lymphoid cells may provide ideas for developing novel and targeted approaches for treatment of IBD.
Literature
1.
2.
Peloquin JM, Goel G, Villablanca EJ, Xavier RJ. Mechanisms of pediatric inflammatory bowel disease. Annu Rev Immunol. 2016;34:31–64PubMed
3.
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis. Lancet. 2017;389:1756–1770PubMed
4.
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet (London, England). 2017;389:1741–1755
5.
Uhlig HH, Powrie F. Translating immunology into therapeutic concepts for inflammatory bowel disease. Annu Rev Immunol. 2018;36:755–781PubMed
6.
de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:739–749PubMed
7.
Breese EB, Corrigan CP, Walker-Smith CJ, MacDonald JA. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology. 1993;78:127–131PubMedPubMedCentral
8.
Rovedatti L, Kudo T, Biancheri P et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009;58:1629–1636PubMed
9.
Liu H, Dasgupta S, Fu Y et al. Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD. BMC Immunol. 2019;20:42PubMedPubMedCentral
10.
Park JH, Jeong DY, Peyrin-Biroulet L, Eisenhut M, Shin JI. Insight into the role of TSLP in inflammatory bowel diseases. Autoimmun Rev. 2017;16:55–63PubMed
11.
Giuffrida P, Caprioli F, Facciotti F, Di Sabatino A. The role of interleukin-13 in chronic inflammatory intestinal disorders. Autoimmun Rev. 2019;18:549–555PubMed
12.
Ealey KN, Koyasu S. How many subsets of innate lymphoid cells do we need? Immunity. 2017;46:10–13PubMed
13.
Simoni Y, Newell EW. Dissecting human ILC heterogeneity: more than just three subsets. Immunology. 2018;153:297–303PubMed
14.
15.
Cupedo T, Crellin NK, Papazian N et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol. 2009;10:66–74PubMed
16.
Cella M, Fuchs A, Vermi W et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009;457:722–725PubMed
17.
Mebius RE, Rennert P, Weissman IL. Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity. 1997;7:493–504PubMed
18.
Huang Y, Mao K, Germain RN. Thinking differently about ILCs-Not just tissue resident and not just the same as CD4(+) T-cell effectors. Immunol Rev. 2018;286:160–171PubMedPubMedCentral
19.
Trabanelli S, Gomez-Cadena A, Salomé B et al. Human innate lymphoid cells (ILCs): Toward a uniform immune-phenotyping. Cytometry B Clin. Cytometry. 2018;94:392–399PubMed
20.
21.
Sonnenberg GF, Hepworth MR. Functional interactions between innate lymphoid cells and adaptive immunity. Nat Rev Immunol. 2019;19:599–613PubMedPubMedCentral
22.
Spits H, Artis D, Colonna M et al. Innate lymphoid cells: a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13:145–149PubMed
23.
Zook EC, Kee BL. Development of innate lymphoid cells. Nat Immunol. 2016;17:775–782PubMed
24.
Lim AI, Verrier T, Vosshenrich CAJ, Di Santo JP. Developmental options and functional plasticity of innate lymphoid cells. Curr. Opin. Immunol. 2017;44:61–68PubMed
25.
Eberl G, Colonna M, Di Santo JP, McKenzie ANJ. Innate lymphoid cells: a new paradigm in immunology. Science. 2015;348:6566
26.
Zhang J, Marotel M, Fauteux-Daniel S et al. T-bet and Eomes govern differentiation and function of mouse and human NK cells and ILC1. Eur J Immunol. 2018;48:738–750PubMed
27.
Poggi A, Benelli R, Vene R et al. Human gut-associated natural killer cells in health and disease. Front Immunol. 2019;10:961PubMedPubMedCentral
28.
Bernink JH, Peters CP, Munneke M et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol. 2013;14:221–229PubMed
29.
Fuchs A, Vermi W, Lee JS et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity. 2013;38:769–781PubMedPubMedCentral
30.
Hwang YY, McKenzie AN. Innate lymphoid cells in immunity and disease. Adv Exp Med Biol. 2013;785:9–26PubMed
31.
Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019;105:1319–1329PubMed
32.
Campos TM, Novais FO, Saldanha M, et al. Granzyme B produced by natural killer cells enhances inflammatory response and contributes to the immunopathology of cutaneous leishmaniasis. J Infect Dis. 2019.
33.
Klein Wolterink RG, Serafini N, van Nimwegen M et al. Essential, dose-dependent role for the transcription factor Gata3 in the development of IL-5+ and IL-13+ type 2 innate lymphoid cells. Proc Natl Acad Sci USA 2013;110:10240–10245PubMedPubMedCentral
34.
Hoyler T, Klose Christoph SN, Souabni A et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity. 2012;37:634–648PubMedPubMedCentral
35.
Spooner CJ, Lesch J, Yan D et al. Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1. Nat Immunol. 2013;14:1229–1236PubMed
36.
Yu Y, Wang C, Clare S et al. The transcription factor Bcl11b is specifically expressed in group 2 innate lymphoid cells and is essential for their development. J Exp Med. 2015;212:865–874PubMedPubMedCentral
37.
38.
Jiang M, Tao S, Zhang S et al. Type 2 innate lymphoid cells participate in IL-33-stimulated Th2-associated immune response in chronic obstructive pulmonary disease. Exp Ther Med. 2019;18:3109–3116PubMedPubMedCentral
39.
Helfrich S, Mindt BC, Fritz JH, Duerr CU. Group 2 innate lymphoid cells in respiratory allergic inflammation. Front Immunol. 2019;10:930PubMedPubMedCentral
40.
Herbert DR, Douglas B, Zullo K. Group 2 innate lymphoid cells (ILC2): type 2 immunity and helminth immunity. Int J Mol Sci. 2019;20:2276PubMedCentral
41.
Rafei-Shamsabadi DA, Klose CSN, Halim TYF, Tanriver Y, Jakob T. Context dependent role of type 2 innate lymphoid cells in allergic skin inflammation. Front Immunol. 2019;10:2591PubMedPubMedCentral
42.
Qiu J, Heller JJ, Guo X et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity. 2012;36:92–104PubMed
43.
Britanova L, Diefenbach A. Interplay of innate lymphoid cells and the microbiota. Immunol Rev. 2017;279:36–51PubMed
44.
Reboldi A, Arnon TI, Rodda LB, Atakilit A, Sheppard D, Cyster JG. IgA production requires B cell interaction with subepithelial dendritic cells in Peyers patches. Science. 2016;352:4822
45.
Kruglov AA, Grivennikov SI, Kuprash DV et al. Nonredundant function of soluble LTalpha3 produced by innate lymphoid cells in intestinal homeostasis. Science. 2013;342:1243–1246PubMed
46.
Takatori H, Kanno Y, Watford WT et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med. 2009;206:35–41PubMedPubMedCentral
47.
Klose CS, Kiss EA, Schwierzeck V et al. A T-bet gradient controls the fate and function of CCR6-RORgammat+ innate lymphoid cells. Nature. 2013;494:261–265PubMed
48.
Mackley EC, Houston S, Marriott CL et al. CCR7-dependent trafficking of RORgamma(+) ILCs creates a unique microenvironment within mucosal draining lymph nodes. Nat Commun. 2015;6:5862PubMed
49.
Song C, Lee JS, Gilfillan S et al. Unique and redundant functions of NKp46+ ILC3s in models of intestinal inflammation. J Exp Med. 2015;212:1869–1882PubMedPubMedCentral
50.
Zeng B, Shi S, Ashworth G, Dong C, Liu J, Xing F. ILC3 function as a double-edged sword in inflammatory bowel diseases. Cell Death Disease. 2019;10:315PubMedPubMedCentral
51.
Powell N, Lo JW, Biancheri P et al. Interleukin 6 increases production of cytokines by colonic innate lymphoid cells in mice and patients with chronic intestinal inflammation. Gastroenterology. 2015;149:e15
52.
Pearson C, Thornton EE, McKenzie B et al. ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation. Elife. 2016;5:e10066PubMedPubMedCentral
53.
Giacomin PR, Moy RH, Noti M et al. Epithelial-intrinsic IKKalpha expression regulates group 3 innate lymphoid cell responses and antibacterial immunity. J Exp Med. 2015;212:1513–1528PubMedPubMedCentral
54.
Aparicio-Domingo P, Romera-Hernandez M, Karrich JJ et al. Type 3 innate lymphoid cells maintain intestinal epithelial stem cells after tissue damage. J Exp Med. 2015;212:1783–1791PubMedPubMedCentral
55.
Pantazi E, Powell N. Group 3 ILCs: peacekeepers or troublemakers? What’s Your Gut Telling You?! Front Immunol. 2019;10:676PubMedPubMedCentral
56.
Gronke K, Hernandez PP, Zimmermann J et al. Interleukin-22 protects intestinal stem cells against genotoxic stress. Nature. 2019;566:249–253PubMedPubMedCentral
57.
Geremia A, Arancibia-Carcamo CV, Fleming MP et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011;208:1127–1133PubMedPubMedCentral
58.
Diefenbach A, Colonna M, Koyasu S. Development, differentiation, and diversity of innate lymphoid cells. Immunity. 2014;41:354–365PubMedPubMedCentral
59.
Bernink Jochem H, Krabbendam L, Germar K et al. Interleukin-12 and -23 control plasticity of CD127+ Group 1 and Group 3 innate lymphoid cells in the intestinal lamina propria. Immunity. 2015;43:146–160PubMed
60.
Teunissen MBM, Munneke JM, Bernink JH et al. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR + ILC3 in lesional skin and blood of psoriasis patients. J Invest Dermatol. 2014;134:2351–2360PubMed
61.
Viant C, Rankin LC, Girard-Madoux MJ, et al. Transforming growth factor-beta and Notch ligands act as opposing environmental cues in regulating the plasticity of type 3 innate lymphoid cells. Sci Signal. 2016;9:ra46.
62.
Chea S, Perchet T, Petit M, et al. Notch signaling in group 3 innate lymphoid cells modulates their plasticity. Sci Signal. 2016;9:ra45.
63.
Ebbo M, Crinier A, Vely F, Vivier E. Innate lymphoid cells: major players in inflammatory diseases. Nat Rev Immunol. 2017;17:665–678PubMed
64.
Lim AI, Menegatti S, Bustamante J et al. IL-12 drives functional plasticity of human group 2 innate lymphoid cells. J Exp Med. 2016;213:569–583PubMedPubMedCentral
65.
Li S, Bostick JW, Ye J et al. Aryl Hydrocarbon receptor signaling cell intrinsically inhibits intestinal group 2 innate lymphoid cell function. Immunity. 2018;49:915PubMedPubMedCentral
66.
Forkel M, van Tol S, Hoog C, Michaelsson J, Almer S, Mjosberg J. Distinct Alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established crohn’s disease and ulcerative colitis. J Crohns Colitis. 2019;13:67–78PubMed
67.
Kinnebrew MA, Buffie CG, Diehl GE et al. Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity. 2012;36:276–287PubMedPubMedCentral
68.
Goto Y, Obata T, Kunisawa J et al. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science. 2014;345:1254009PubMedPubMedCentral
69.
Tsai PY, Zhang B, He WQ et al. IL-22 upregulates epithelial claudin-2 to drive diarrhea and enteric pathogen clearance. Cell Host Microbe. 2017;21:e4
70.
Kobori A, Yagi Y, Imaeda H et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol. 2010;45:999–1007PubMed
71.
Schwartz C, O’Grady K, Lavelle EC, Fallon PG. Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer. Eur J Immunol. 2016;46:1091–1100PubMed
72.
Monticelli LA, Osborne LC, Noti M, Tran SV, Zaiss DM, Artis D. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA 2015;112:10762–10767PubMedPubMedCentral
73.
Schiering C, Krausgruber T, Chomka A et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513:564–568PubMedPubMedCentral
74.
Forkel M, van Tol S, Höög C, Michaëlsson J, Almer S, Mjösberg J. Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established crohn’s disease and ulcerative colitis. J Crohns Colitis. 2019;13:67–78PubMed
75.
Camelo A, Barlow JL, Drynan LF et al. Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. J Gastroenterol. 2012;47:1198–1211PubMedPubMedCentral
76.
Zelante T, Iannitti RG, Cunha C et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39:372–385PubMed
77.
Qiu J, Guo X, Chen ZM et al. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity. 2013;39:386–399PubMed
78.
Ganal-Vonarburg SC, Duerr CU. The interaction of intestinal microbiota and innate lymphoid cells in health and disease throughout life. Immunology. 2020;159:39–51PubMed
79.
Constantinides MG. Interactions between the microbiota and innate and innate-like lymphocytes. J Leukoc Biol. 2018;103:409–419PubMed
80.
Blander JM, Longman RS, Iliev ID, Sonnenberg GF, Artis D. Regulation of inflammation by microbiota interactions with the host. Nat Immunol. 2017;18:851–860PubMedPubMedCentral
81.
Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016;535:65–74PubMed
82.
Sawa S, Lochner M, Satoh-Takayama N et al. RORgammat+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat Immunol. 2011;12:320–326PubMed
83.
Sonnenberg GF, Monticelli LA, Alenghat T et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science. 2012;336:1321–1325PubMedPubMedCentral
84.
Penny HA, Hodge SH, Hepworth MR. Orchestration of intestinal homeostasis and tolerance by group 3 innate lymphoid cells. Semin Immunopathol. 2018;40:357–370PubMedPubMedCentral
85.
Castleman MJ, Dillon SM, Purba CM et al. Commensal and pathogenic bacteria indirectly induce IL-22 but Not IFNgamma production from human colonic ILC3s via multiple mechanisms. Front Immunol. 2019;10:649PubMedPubMedCentral
86.
Babu ST, Niu X, Raetz M, Savani RC, Hooper LV, Mirpuri J. Maternal high-fat diet results in microbiota-dependent expansion of ILC3s in mice offspring. JCI Insight. 2018;3.
87.
Zhou L, Chu C, Teng F et al. Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2. Nature. 2019;568:405–409PubMedPubMedCentral
88.
Wang Y, Kuang Z, Yu X, Ruhn KA, Kubo M, Hooper LV. The intestinal microbiota regulates body composition through NFIL3 and the circadian clock. Science. 2017;357:912–916PubMedPubMedCentral
89.
Godinho-Silva C, Domingues RG, Rendas M, et al. Light-entrained and brain-tuned circadian circuits regulate ILC3s and gut homeostasis. Nature. 2019.
90.
Teng F, Goc J, Zhou L, et al. A circadian clock is essential for homeostasis of group 3 innate lymphoid cells in the gut. Sci Immunol. 2019;4.
91.
von Moltke J, Ji M, Liang HE, Locksley RM. Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit. Nature. 2016;529:221–225
92.
Frisbee AL, Saleh MM, Young MK et al. IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection. Nat Commun. 2019;10:2712PubMedPubMedCentral
93.
Garrido-Mesa N, Schroeder JH, Stolarczyk E et al. T-bet controls intestinal mucosa immune responses via repression of type 2 innate lymphoid cell function. Mucosal Immunol. 2019;12:51–63PubMed
94.
Sepahi A, Liu Q, Friesen L, Kim CH. Dietary fiber metabolites regulate innate lymphoid cell responses. Mucosal Immunol. 2020.
95.
Lloyd-Price J, Arze C, Ananthakrishnan AN et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569:655–662PubMedPubMedCentral
96.
Lamas B, Richard ML, Leducq V et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016;22:598–605PubMedPubMedCentral
97.
Scott SA, Fu J, Chang PV. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 2020;117:19376–19387PubMedPubMedCentral
98.
Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517:293–301PubMed
99.
Sano T, Huang W, Hall JA et al. An IL-23R/IL-22 circuit regulates epithelial serum amyloid A to promote local effector Th17 responses. Cell. 2015;163:381–393PubMedPubMedCentral
100.
Atarashi K, Tanoue T, Ando M et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell. 2015;163:367–380PubMedPubMedCentral
101.
Mielke LA, Jones SA, Raverdeau M et al. Retinoic acid expression associates with enhanced IL-22 production by gammadelta T cells and innate lymphoid cells and attenuation of intestinal inflammation. J Exp Med. 2013;210:1117–1124PubMedPubMedCentral
102.
Longman RS, Diehl GE, Victorio DA et al. CX(3)CR1(+) mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. J Exp Med. 2014;211:1571–1583PubMedPubMedCentral
103.
Castellanos JG, Woo V, Viladomiu M et al. Microbiota-induced TNF-like ligand 1A drives group 3 innate lymphoid cell-mediated barrier protection and intestinal T cell activation during colitis. Immunity. 2018;49:e5
104.
Mortha A, Chudnovskiy A, Hashimoto D et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science. 2014;343:1249288PubMedPubMedCentral
105.
Levy M, Thaiss CA, Zeevi D et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell. 2015;163:1428–1443PubMedPubMedCentral
106.
Munoz M, Eidenschenk C, Ota N et al. Interleukin-22 induces interleukin-18 expression from epithelial cells during intestinal infection. Immunity. 2015;42:321–331PubMed
107.
Hepworth MR, Fung TC, Masur SH et al. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4(+) T cells. Science. 2015;348:1031–1035PubMedPubMedCentral
108.
Hepworth MR, Monticelli LA, Fung TC et al. Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature. 2013;498:113–117PubMedPubMedCentral
109.
Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269–278PubMed
110.
Withers DR, Hepworth MR, Wang X et al. Transient inhibition of ROR-gammat therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. Nat Med. 2016;22:319–323PubMedPubMedCentral
111.
Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693–1700PubMed
112.
Withers DR, Hepworth MR. Group 3 innate lymphoid cells: communications hubs of the intestinal immune system. Front Immunol. 2017;8:1298PubMedPubMedCentral
113.
Kaser A. Not all monoclonals are created equal-lessons from failed drug trials in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2014;28:437–449PubMed
114.
Colombel JF, Sendid B, Jouault T, Poulain D. Secukinumab failure in Crohn’s disease: the yeast connection? Gut. 2013;62:800–801PubMed
115.
Zhou L, Sonnenberg GF. Essential immunologic orchestrators of intestinal homeostasis. Sci Immunol. 2018;3.
116.
Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2019.
117.
118.
Tang C, Kakuta S, Shimizu K, et al. Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota. Nat Immunol. 2018.
119.
Reinisch W, de Villiers W, Bene L et al. Fontolizumab in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis. 2010;16:233–242PubMed
120.
Goldberg R, Prescott N, Lord GM, MacDonald TT, Powell N. The unusual suspects–innate lymphoid cells as novel therapeutic targets in IBD. Nat Rev Gastroenterol Hepatol. 2015;12:271–283PubMed
121.
Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476PubMed
122.
Pelczar P, Witkowski M, Perez LG et al. A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease. Science. 2016;354:358–362PubMed
123.
Danese S, Vermeire S, Hellstern P et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 2019;68:40–48PubMed
124.
Powell N, Walker AW, Stolarczyk E et al. The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells. Immunity. 2012;37:674–684PubMedPubMedCentral
125.
Ermann J, Staton T, Glickman JN, de Waal Malefyt R, Glimcher LH. Nod/Ripk2 signaling in dendritic cells activates IL-17A-secreting innate lymphoid cells and drives colitis in T-bet-/-.Rag2-/- (TRUC) mice. Proc Natl Acad Sci USA. 2014;111:E2559-66.
Metadata
Title
Update: Innate Lymphoid Cells in Inflammatory Bowel Disease
Authors
Weiwei Luo
Li Tian
Bei Tan
Zhaohua Shen
Mengwei Xiao
Shuai Wu
Xiangrui Meng
Xing Wu
Xiaoyan Wang
Publication date
01-01-2022
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-06831-8

Other articles of this Issue 1/2022

Digestive Diseases and Sciences 1/2022 Go to the issue

Original Article

Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma

Original Article

Role of Liver Biopsy in Assessment of Radiologically Identified Liver Masses

Correspondence

C. difficile in COVID-19 Patients: Is It a Colonization Issue?

Review

New Insights into the Role of Oral Microbiota Dysbiosis in the Pathogenesis of Inflammatory Bowel Disease

Original Article

Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study

Original Article

Comparative Efficacy of Various Pharmacological Interventions in the Treatment of Functional Dyspepsia: A Network Meta-Analysis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits